Alligator Bioscience マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Søren Bregenholt

最高経営責任者

SEK 5.2m

報酬総額

CEO給与比率	68.9%
CEO在任期間	3.4yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

CEO報酬分析

Alligator Bioscience の収益と比較して、Søren Bregenholt の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 248m
Jun 30 2024	n/a	n/a	-SEK 234m
Mar 31 2024	n/a	n/a	-SEK 249m
Dec 31 2023	SEK 5m	SEK 4m	-SEK 249m
Sep 30 2023	n/a	n/a	-SEK 232m
Jun 30 2023	n/a	n/a	-SEK 231m
Mar 31 2023	n/a	n/a	-SEK 213m
Dec 31 2022	SEK 4m	SEK 3m	-SEK 193m
Sep 30 2022	n/a	n/a	-SEK 177m
Jun 30 2022	n/a	n/a	-SEK 163m
Mar 31 2022	n/a	n/a	-SEK 152m
Dec 31 2021	SEK 4m	SEK 2m	-SEK 142m

報酬と市場: Sørenの総報酬 ($USD 470.97K ) は、 UK市場 ($USD 354.22K ) の同規模の企業の平均を上回っています。

報酬と収益: Sørenの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Søren Bregenholt (53 yo)

3.4yrs

在職期間

SEK 5,201,000

報酬

Mr. Søren Bregenholt, Ph D serves as the Chief Executive Officer at Alligator Bioscience AB (publ) since June 01, 2021. He served as the Chief Operating Officer of Symphogen A/S.Mr. Bregenholt served as S...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Søren Bregenholt	Chief Executive Officer	3.4yrs	SEK 5.20m	データなし
Johan Gileus	Chief Financial Officer	less than a year	データなし	データなし
Laura von Schantz	Chief Technology Officer	2.8yrs	データなし	0.00035% SEK 1.4k
Peter Ellmark	Chief Scientific Officer	3.8yrs	データなし	データなし
Greta Eklund	Investor Relations & Communications Manager	no data	データなし	データなし
Sumeet Ambarkhane	Chief Medical Officer	2.8yrs	データなし	データなし

2.8yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: 0RK9の経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Staffan Encrantz	Independent Director	2.5yrs	SEK 300.00k	データなし
Anders Ekblom	Independent Chairman of the Board	7.5yrs	SEK 700.00k	0.015% SEK 61.4k
Hans-Peter Ostler	Independent Vice Chairman of the Board	3.4yrs	SEK 525.00k	データなし
Denise Goode	Independent Director	2.5yrs	SEK 350.00k	データなし
Eva Saers	Independent Director	3.4yrs	SEK 350.00k	データなし
Karin Nordbladh	Employee Representative Director	1.8yrs	データなし	データなし

3.0yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: 0RK9の取締役会は経験豊富ではない ( 3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Alligator Bioscience マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

High number of new directors

High number of new directors

Recent updates

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023)

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Second quarter 2024 earnings released: kr0.066 loss per share (vs kr0.19 loss in 2Q 2023)

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

High number of new directors

High number of new directors

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

High number of new and inexperienced directors

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

High number of new directors

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

High number of new directors

First quarter 2023 earnings released: kr0.28 loss per share (vs kr0.20 loss in 1Q 2022)

High number of new directors

High number of new directors

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

High number of new directors

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

High number of new directors

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Less than half of directors are independent

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14